Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a prominent Chinese pharmaceutical company, has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its PD-L1 monoclonal antibody (mAb) adebrelimab (SHR-1316) in combination with chemotherapy as adjuvant therapy for patients with resectable stage II or III EGFR mutated non-small cell lung cancer (NSCLC).
Adebrelimab, which has already been approved in China for the first-line treatment of extensive stage small-cell lung cancer (ES-SCLC) in combination with chemotherapy since March of the previous year, is now set to be evaluated in a new therapeutic context. This investigational use aims to explore the potential benefits of adebrelimab in the adjuvant setting for EGFR mutated NSCLC patients, building on the drug’s established profile in lung cancer treatment.
The clinical study’s approval highlights Hengrui’s commitment to expanding the application of its immunotherapeutic agents and underscores the company’s efforts to improve outcomes for patients with various types of lung cancer.- Flcube.com